While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Ottawa, Precedence Research, April 16, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the worldwide generic drugs market size was valued at USD 445.62 billion in 2024 and is projected ...

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers and industry experts, who warn that such a move could lead to increased drug ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

With this launch, Lupin's FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to ...

The news has been welcomed by healthcare activists and patients as a significant development ... would allow the manufacture of the generic version of the drug and ensure procurement of medicine ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured at ...

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Trump’s push to bring drug manufacturing back to the United States has sparked concerns across the industry, particularly for generic drugmakers already operating under tight margins.